Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer.
説明 | LY2090314, an effective GSK-3α/β inhibitor (IC50: 1.5 nM/0.9 nM), may improve the efficacy of platinum-based chemotherapy regimens. LY2090314 has been used in trials studying the treatment of Leukemia, Advanced Cancer, and Pancreatic Cancer. |
ターゲット&IC50 | GSK-3α:1.5 nM, GSK-3β:0.9 nM |
In vivo | LY2090314 enhances the efficacy of cisplatin and carboplatin in solid tumor cancer xenografts. [1] |
分子量 | 512.53 |
分子式 | C28H25FN6O3 |
CAS No. | 603288-22-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 93 mg/mL (181.5 mM)
Ethanol: 2 mg/mL (3.9 mM), Heating is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LY2090314 603288-22-8 PI3K/Akt/mTOR signaling Stem Cells GSK-3 LY 2090314 Inhibitor LY-2090314 inhibit Glycogen synthase kinase 3 Glycogen synthase kinase-3 inhibitor